drugset / Trial / NCT07170319
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
Phase 1
Active not recruiting
79 enrolled
Innovent Biologics Technology Limited (Shanghai R&D Center)
RandomizedSequentialDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.
Timeline
- Start
- 2025-09-25
- Primary completion
- 2025-12-24
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI3032 | Unknown | — | Oral |